Switzerland
  • Europe
    • FR
    • DE
    • IT
    • ES
    • BE
    • NL
    • LU
    • DK
    • PL
    • UK
  • Switzerland
    • Basel
    • Bern
    • Geneva
    • Lausanne
    • Zürich
  • Schweiz
  • Suisse
  • Alps
  • Business
    • ABB
    • Chubb
    • Glencore
    • Nestlé
    • Novartis
    • Roche
    • UBS
    • Vitol
    • Zurich Insurance
  • NATO
  • US
  • Africa
  • Afrique

Categories

  • ABB
  • Alps
  • Basel
  • Bern
  • Chubb
  • Geneva
  • Glencore
  • Lausanne
  • Nestlé
  • Novartis
  • Roche
  • Switzerland
  • UBS
  • Vitol
  • Zürich
  • Zurich Insurance
Switzerland
  • Europe
    • FR
    • DE
    • IT
    • ES
    • BE
    • NL
    • LU
    • DK
    • PL
    • UK
  • Switzerland
    • Basel
    • Bern
    • Geneva
    • Lausanne
    • Zürich
  • Schweiz
  • Suisse
  • Alps
  • Business
    • ABB
    • Chubb
    • Glencore
    • Nestlé
    • Novartis
    • Roche
    • UBS
    • Vitol
    • Zurich Insurance
  • NATO
  • US
  • Africa
  • Afrique

Browsing Tag

teriflunomide

4 posts
RRoche
Data show Roche’s sixth-generation Troponin T test offers a new level of accuracy critical for diagnosing heart attacks
Read More

Roche’s fenebrutinib significantly reduced relapses versus standard of care to approximately one every 17 years in RMS

  • 2026-04-27
F. Hoffmann-La Roche Ltd Late-breaking Phase III FENhance 1 and 2 study results showed superiority of investigational fenebrutinib…
RRoche
Genentech petrelintide sheds 10.7% weight in Phase II
Read More

Genentech fenebrutinib slashes MS relapses 51%

  • 2026-03-13
03/02/2026 – 01:10 AM – FENhance 1 met its primary endpoint, showing investigational fenebrutinib significantly reduced relapses by…
RRoche
Roche's BTK Drug Fenebrutinib Shines in Multiple Sclerosis Study
Read More

Roche’s BTK Drug Fenebrutinib Shines in Multiple Sclerosis Study

  • 2026-03-06
Roche RHHBY recently announced that the late-stage study, FENhance 1, evaluating fenebrutinib for relapsing multiple sclerosis (RMS), met…
RRoche
Roche's BTK Drug Fenebrutinib Shines in Multiple Sclerosis Study
Read More

Roche’s BTK Drug Fenebrutinib Shines in Multiple Sclerosis Study

  • 2026-03-03
Roche RHHBY recently announced that the late-stage study, FENhance 1, evaluating fenebrutinib for relapsing multiple sclerosis (RMS), met…
Switzerland
www.europesays.com